Objective To evaluate the effectiveness and safety of Su Fei He Ji combined with anlotinib hydrochloride in the treatment of refractory advanced non-small cell lung cancer(NSCLC)patients presenting with phlegm stasis obstructing lung type.Methods Thirty-nine patients with advanced NSCLC were randomly assigned to either a control group(19 patients)or an experimental group(20 patients).The control group received treatment with anlotinib alone,while the experimental group received an additional oral administration of Su Fei He Ji.A comparative analysis was conducted between the two groups based on various parameters including short-term objective therapeutic efficacy,progression-free survival,TCM syndrome scores,KPS scores,weight changes,related tumor markers,incidence of adverse reactions,and variations in plasma concentrations of anlotinib.Results Following treatment,the objective response rate was 5%and the disease control rate was 85%in the experimental group,while the control group showed an objective response rate of 0%and a disease control rate of 78.95%.No statistically significant difference was observed in short-term objective efficacy between the two groups(P>0.05).Notably,the experimental group exhibited a significant improvement compared to the control group in various aspects,including TCM syndrome scores and KPS scores(P<0.05).Conversely,no significant differences were observed in weight changes or the reduction levels of other tumor markers(CEA,SCC,CA125,CA199,CYFRA21-1)(P>0.05).Moreover,the incidence of fatigue was notably lower in the experimental group(P<0.05),while no statistical difference was evident in the occurrence of other adverse reactions,such as hypertension,rash,and bleeding,between the two groups(P>0.05).It is important to highlight that there was no statistically significant variance in plasma concentrations between the groups(P>0.05),and no significant correlation was identified between plasma concentrations and the incidence of adverse reactions(P>0.05).Conclusion The combination of Su Fei He Ji and anlotinib hydrochloride effectively improves clinical symptoms and quality of life,and reduces adverse reactions in advanced NSCLC patients.This is achieved without affecting the plasma concentrations of anlotinib.

Objective:To explore relationship between early fluid balance and phenotypic changes of Treg in patients with sep-sis in ICU and its influence on prognosis.Methods:Ninety-eight patients with sepsis admitted to Wuxi Fifth People's Hospital from June 2018 to June 2023 were selected as study objects,and divided into death group(n=34)and survival group(n=64)according to whether patients died within 28 days after admission to ICU.Clinical data,fluid balance,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels after 24 h and 72 h in ICU were compared between two groups.Multivariate Logistic regression was used to analyze correlation between fluid balance and CD4+CD25+Foxp3+Treg and CD4+CD25+Treg.Influencing factors of death in patients with sepsis in ICU were screened and corresponding prediction model was established.Results:Age,sequential organ failure assessment(SOFA)score,acute physiology and chronic health evaluation(APACHE Ⅱ)score,fluid balance 24 h and 72 h after ICU admission,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels were significantly higher than survival group(P<0.05).Multivariate Logistic regres-sion analysis showed that age,SOFA score,APACHE Ⅱ score,fluid balance at 24 h and 72 h after ICU admission,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels at 24 h after ICU admission were all risk factors for death at 28 days after ICU admission(P<0.05).Combined with the above five factors to build a predictive model with high sensitivity and accuracy.Conclusion:Higher fluid balance and CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels are risk factors for death in patients with sepsis in ICU,and they are significantly positively correlated.

Objective To evaluate the effectiveness and safety of Su Fei He Ji combined with anlotinib hydrochloride in the treatment of refractory advanced non-small cell lung cancer(NSCLC)patients presenting with phlegm stasis obstructing lung type.Methods Thirty-nine patients with advanced NSCLC were randomly assigned to either a control group(19 patients)or an experimental group(20 patients).The control group received treatment with anlotinib alone,while the experimental group received an additional oral administration of Su Fei He Ji.A comparative analysis was conducted between the two groups based on various parameters including short-term objective therapeutic efficacy,progression-free survival,TCM syndrome scores,KPS scores,weight changes,related tumor markers,incidence of adverse reactions,and variations in plasma concentrations of anlotinib.Results Following treatment,the objective response rate was 5%and the disease control rate was 85%in the experimental group,while the control group showed an objective response rate of 0%and a disease control rate of 78.95%.No statistically significant difference was observed in short-term objective efficacy between the two groups(P>0.05).Notably,the experimental group exhibited a significant improvement compared to the control group in various aspects,including TCM syndrome scores and KPS scores(P<0.05).Conversely,no significant differences were observed in weight changes or the reduction levels of other tumor markers(CEA,SCC,CA125,CA199,CYFRA21-1)(P>0.05).Moreover,the incidence of fatigue was notably lower in the experimental group(P<0.05),while no statistical difference was evident in the occurrence of other adverse reactions,such as hypertension,rash,and bleeding,between the two groups(P>0.05).It is important to highlight that there was no statistically significant variance in plasma concentrations between the groups(P>0.05),and no significant correlation was identified between plasma concentrations and the incidence of adverse reactions(P>0.05).Conclusion The combination of Su Fei He Ji and anlotinib hydrochloride effectively improves clinical symptoms and quality of life,and reduces adverse reactions in advanced NSCLC patients.This is achieved without affecting the plasma concentrations of anlotinib.

Objective:To explore relationship between early fluid balance and phenotypic changes of Treg in patients with sep-sis in ICU and its influence on prognosis.Methods:Ninety-eight patients with sepsis admitted to Wuxi Fifth People's Hospital from June 2018 to June 2023 were selected as study objects,and divided into death group(n=34)and survival group(n=64)according to whether patients died within 28 days after admission to ICU.Clinical data,fluid balance,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels after 24 h and 72 h in ICU were compared between two groups.Multivariate Logistic regression was used to analyze correlation between fluid balance and CD4+CD25+Foxp3+Treg and CD4+CD25+Treg.Influencing factors of death in patients with sepsis in ICU were screened and corresponding prediction model was established.Results:Age,sequential organ failure assessment(SOFA)score,acute physiology and chronic health evaluation(APACHE Ⅱ)score,fluid balance 24 h and 72 h after ICU admission,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels were significantly higher than survival group(P<0.05).Multivariate Logistic regres-sion analysis showed that age,SOFA score,APACHE Ⅱ score,fluid balance at 24 h and 72 h after ICU admission,CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels at 24 h after ICU admission were all risk factors for death at 28 days after ICU admission(P<0.05).Combined with the above five factors to build a predictive model with high sensitivity and accuracy.Conclusion:Higher fluid balance and CD4+CD25+Foxp3+Treg and CD4+CD25+Treg levels are risk factors for death in patients with sepsis in ICU,and they are significantly positively correlated.